Roth Capital Predicts Cronos Group Q1 Earnings

Key Points

• Roth Capital estimates that Cronos Group will earn $0.01 per share in Q1 2026, with a consensus estimate for the full year at a loss of ($0.03) per share.
• Wall Street Zen downgraded Cronos Group's rating from "hold" to "sell," indicating a bearish outlook.
• Cronos Group's latest earnings report showed a loss of ($0.10) EPS, missing estimates, with revenue of $33.46 million compared to expectations of $45.73 million.

Cronos Group Inc. (NASDAQ:CRON - Free Report) - Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for Cronos Group in a research report issued on Thursday, August 7th. Roth Capital analyst W. Kirk anticipates that the company will earn $0.01 per share for the quarter. The consensus estimate for Cronos Group's current full-year earnings is ($0.03) per share. Roth Capital also issued estimates for Cronos Group's Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.06 EPS.

Separately, Wall Street Zen cut Cronos Group from a "hold" rating to a "sell" rating in a research note on Saturday.

Cronos Group Price Performance

NASDAQ CRON opened at $2.30 on Monday. The business has a fifty day moving average price of $2.00 and a two-hundred day moving average price of $1.93. Cronos Group has a fifty-two week low of $1.60 and a fifty-two week high of $2.46. The stock has a market capitalization of $882.76 million, a PE ratio of 46.00 and a beta of 1.01.

Cronos Group (NASDAQ:CRON - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.08). The company had revenue of $33.46 million for the quarter, compared to analyst estimates of $45.73 million. Cronos Group had a negative return on equity of 3.78% and a net margin of 14.19%.

Institutional Investors Weigh In On Cronos Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Cronos Group during the fourth quarter worth $641,000. Millennium Management LLC lifted its stake in shares of Cronos Group by 23.7% in the 4th quarter. Millennium Management LLC now owns 840,374 shares of the company's stock valued at $1,698,000 after acquiring an additional 161,163 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Cronos Group by 5.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,753,055 shares of the company's stock valued at $5,561,000 after acquiring an additional 132,536 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of Cronos Group by 8.0% in the 4th quarter. Two Sigma Advisers LP now owns 275,357 shares of the company's stock valued at $556,000 after acquiring an additional 20,400 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Cronos Group in the 4th quarter valued at $76,000. 8.71% of the stock is currently owned by institutional investors.

About Cronos Group

Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.